Shandong Weigao Group Medical Polymer Co Ltd Class H (HK:1066)
:1066
Want to see HK:1066 full AI Analyst Report?
Top Page
Shandong Weigao Group Medical Polymer Co
(1066)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$3.50
▼(-36.94% Downside)
Action:Reiterated
Date:05/04/26
The score is anchored by mixed fundamentals: a healthy, conservatively leveraged balance sheet offsets sharply weaker recent revenue and margin trends. Technicals are meaningfully bearish with the stock below key moving averages and negative MACD, while valuation helps support the overall rating due to a moderate P/E and high dividend yield.
Positive Factors
Conservative balance sheet
A low, stable debt-to-equity ratio and expanding equity base provide lasting financial resilience. This reduces refinancing and liquidity risk, preserves strategic optionality for capex or M&A, and supports operations through industry cycles over the next several quarters.
Negative Factors
Sharp recent revenue decline
A 40% revenue drop materially erodes scale and operating leverage, weakening long-term earnings power. Sustained top-line contraction can impair R&D and manufacturing efficiency, complicate customer retention, and pressure medium-term profitability and investment plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A low, stable debt-to-equity ratio and expanding equity base provide lasting financial resilience. This reduces refinancing and liquidity risk, preserves strategic optionality for capex or M&A, and supports operations through industry cycles over the next several quarters.
Read all positive factors
Shandong Weigao Group Medical Polymer Co (1066) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$15.65B
Dividend Yield4.58%
Average Volume (3M)10.92M
Price to Earnings (P/E)12.9
Beta (1Y)1.13
Revenue Growth2.34%
EPS Growth-22.25%
CountryHK
Employees12,719
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.35
Shares Outstanding4,522,332,500
10 Day Avg. Volume7,849,305
30 Day Avg. Volume10,915,466
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)0.86
Price to Sales (P/S)1.55
P/FCF Ratio12.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.62Price Target Upside1.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.38
Revenue Forecast (FY)HK$14.19B
Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model
Company Description
Shandong Weigao Group Medical Polymer Co., Ltd. is a leading Chinese manufacturer specializing in the production of medical devices and polymer products. Established in 1992, the company operates primarily in the healthcare sector, offering a dive...
How the Company Makes Money
null...
Shandong Weigao Group Medical Polymer Co Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.39B | 13.09B | 13.23B | 13.62B | 13.15B |
| Gross Profit | 6.33B | 6.58B | 6.64B | 7.31B | 7.35B |
| EBITDA | 2.75B | 3.14B | 3.55B | 4.38B | 3.75B |
| Net Income | 1.61B | 2.07B | 2.00B | 2.76B | 2.28B |
Balance Sheet | |||||
| Total Assets | 36.06B | 34.76B | 33.67B | 33.20B | 30.37B |
| Cash, Cash Equivalents and Short-Term Investments | 9.87B | 8.32B | 7.33B | 7.49B | 7.13B |
| Total Debt | 5.99B | 4.19B | 4.17B | 4.49B | 4.14B |
| Total Liabilities | 10.23B | 9.42B | 9.68B | 9.75B | 9.46B |
| Stockholders Equity | 24.12B | 23.75B | 22.45B | 21.67B | 19.27B |
Cash Flow | |||||
| Free Cash Flow | 1.72B | 2.19B | 2.11B | 1.10B | 1.92B |
| Operating Cash Flow | 2.55B | 2.79B | 2.80B | 2.21B | 3.04B |
| Investing Cash Flow | -382.91M | -1.10B | -1.39B | -2.57B | -1.48B |
| Financing Cash Flow | -772.65M | -1.60B | -2.16B | -1.02B | -547.92M |
Shandong Weigao Group Medical Polymer Co Technical Analysis
Negative
5.55
Price Trends
3.93
Negative
4.56
Negative
5.19
Negative
Market Momentum
-0.11
Negative
42.25
Neutral
41.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1066, the sentiment is Negative. The current price of 5.55 is above the 20-day moving average (MA) of 3.52, above the 50-day MA of 3.93, and above the 200-day MA of 5.19, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 42.25 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1066.
Shandong Weigao Group Medical Polymer Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$3.33B | 9.15 | 10.21% | 2.70% | 9.88% | 5.65% | |
77 Outperform | HK$5.37B | 8.37 | 16.76% | 3.65% | 11.07% | 48.01% | |
69 Neutral | HK$7.40B | 21.45 | 11.20% | ― | 25.24% | 7.29% | |
67 Neutral | HK$1.74B | 18.55 | 3.68% | 7.46% | 7.11% | -34.66% | |
66 Neutral | HK$14.17B | ― | 5.12% | ― | ― | ― | |
62 Neutral | HK$15.65B | 12.88 | 6.64% | 4.58% | 2.34% | -22.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1066
Shandong Weigao Group Medical Polymer Co
3.52
-2.05
-36.84%
HK:1358
PW Medtech Group Ltd.
1.18
0.20
20.65%
HK:3600
Modern Dental Group Limited
5.70
1.81
46.45%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
34.90
9.40
36.86%
HK:6699
Angelalign Technology Inc.
73.55
22.53
44.17%
HK:6929
OrbusNeich Medical Group Holdings Limited
4.05
0.46
12.81%
Shandong Weigao Group Medical Polymer Co Corporate Events
Shandong Weigao Sets Up Korea-Focused Fund in Connected Deal
Apr 30, 2026
Shandong Weigao Group Medical Polymer has moved to deepen its investment footprint by setting up a Korea-focused private fund through its indirect wholly owned unit, Wego Healthcare Fund. The vehicle will target small and mid-sized enterprises in ...
Weigao Group Issues Overseas Regulatory Notice on Subsidiary’s SSE Disclosure
Apr 29, 2026
Shandong Weigao Group Medical Polymer Company Limited announced that its subsidiary, Shandong Weigao Orthopaedic Device Company Limited, has published an announcement on the Shanghai Stock Exchange’s website in accordance with PRC regulatory...
Weigao Medical Polymer Sets AGM to Approve Dividend and Tightened Share-Issue Mandate
Apr 28, 2026
Shandong Weigao Group Medical Polymer Company Limited has convened its 2026 annual general meeting for 29 May in Weihai, Shandong, where shareholders will review and approve the audited 2025 financial statements, the board and Supervisory Committe...
Shandong Weigao Wins CSRC Approval for H Share Full Circulation Plan
Apr 1, 2026
Shandong Weigao Group Medical Polymer Company Limited has received a filing notice from the China Securities Regulatory Commission approving its plan for H share full circulation. The approval covers the conversion of 48,300,000 previously unliste...
Weigao Group Flags Orthopaedic Unit Disclosure on Shanghai Exchange
Mar 27, 2026
Shandong Weigao Group Medical Polymer Company Limited, a Hong Kong-listed Chinese medical device maker specializing in polymer-based products, oversees a broad portfolio that includes its orthopaedic subsidiary, Shandong Weigao Orthopaedic Device ...
Shandong Weigao flags Shanghai disclosure by orthopaedic subsidiary to Hong Kong investors
Mar 27, 2026
Shandong Weigao Group Medical Polymer Company Limited has issued an overseas regulatory announcement to inform Hong Kong investors that its subsidiary, Shandong Weigao Orthopaedic Device Company Limited, has published an announcement on the Shangh...
Shandong Weigao Buys Connected Party Industrial Land Use Right in Weihai
Mar 27, 2026
Shandong Weigao Group Medical Polymer Company Limited has agreed to acquire the land use right for an industrial plot in Weihai City, Shandong Province, from its connected party Weigao Biotechnology for RMB39.71 million. The land, measuring about ...
Shandong Weigao Adopts Formal Board Diversity Policy
Mar 27, 2026
Shandong Weigao Group Medical Polymer Company Limited has formally adopted a Board Diversity Policy to guide the composition and appointment of its directors. The company underscores that a mix of skills, regional and industry experience, backgrou...
Shandong Weigao Sets Comprehensive Workforce Diversity and Inclusion Policy
Mar 27, 2026
Shandong Weigao Group Medical Polymer Company Limited has adopted a formal workforce diversity policy that emphasizes building a diverse and inclusive senior management and wider workforce to support sustainable operations and enhance shareholder ...
Shandong Weigao Group Announces Final 2025 Cash Dividend of RMB 0.06 per Share
Mar 27, 2026
Shandong Weigao Group Medical Polymer Company Limited has declared a final ordinary cash dividend of RMB 0.06 per share for the financial year ended 31 December 2025, reflecting its profit distribution strategy to shareholders. The dividend is sub...
Weigao’s Profit Drops Despite Modest Revenue Growth and Dividend Cut
Mar 27, 2026
Shandong Weigao Group Medical Polymer Company Limited, a major Chinese medical device producer specializing in polymer-based products and hospital consumables, operates in the broader healthcare and medtech sector with a focus on serving clinical ...
Weigao Medical Polymer Sets March Board Meeting to Approve 2025 Results and Mull Final Dividend
Mar 3, 2026
Shandong Weigao Group Medical Polymer Company Limited has scheduled a board meeting for 27 March 2026 to review and approve the audited annual results for the financial year ended 31 December 2025. The board will also consider the proposal and pot...
Weigao Group Flags Subsidiary Disclosure on Shanghai Stock Exchange
Feb 27, 2026
Shandong Weigao Group Medical Polymer Company Limited announced that, in accordance with Hong Kong listing disclosure rules, it is drawing investors’ attention to an announcement by its subsidiary, Shandong Weigao Orthopaedic Device Company ...
Weigao Medical Shareholders Approve Key Transaction Documents at Extraordinary Meeting
Feb 12, 2026
Shandong Weigao Group Medical Polymer Company Limited has announced that its first extraordinary general meeting of 2026, held on 12 February in Hong Kong, duly approved an ordinary resolution by poll. Shareholders voted in favour of a series of t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.